On August 26, 2019, Ms. Ye Yizuo, Director of the International Business Department of ROHTO Pharmaceutical Co.,Ltd.visited GuoSAFE Hebei Pharmaceutical Technology Co., Ltd. (GuoSAFE) to discuss the cooperation on medical evaluation. Deputy Director Han Gang showed them around. Ms. Ye Yizuo spoke highly of the hardware, software and technical team capabilities of the National Assessment Center’s safety assessment laboratory that met the highest standards of FDA and NMPA.
ROHTO Pharmaceutical Co., Ltd., a well-known listed pharmaceutical company in Japan, born in 1899 and has now become a synonym for eye drops. It is also actively expanded its research and development capabilities in innovative biologics, in the field of innovative biological products and has leading core technology in the research and development of cell therapy products, biotech drugs and medical device products.
The focus of this negotiation is to discuss the preclinical and clinical research and development details of ophthalmic drugs that ROHTO Pharmaceutical Co.,Ltd. intends to enter the Chinese market. Director Dong Yansheng led the expert team of the safety evaluation center to answer questions about metabolism, safety evaluation and clinical analysis in the research and development of ophthalmic drugs of ROHTO, Japan. And a more comprehensive cooperation will be carried out in the design and research of different modules to helpROHTO products better serve Chinese customers.